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1. Introduction
According to epidemiological studies, rates of social anxiety disorder 
(SAD) or social phobia range from 3% to 16% in the general 
population.[1,2] Social phobia and specific phobias have an earlier age 
of onset than other anxiety disorders. The median age of onset for the 
disorder is 13 years with an onset after age 25 relatively uncommon. 
The disorder typically persists throughout adult life and is associated 
with significant functional impairment.[3-5] Individuals with SAD are 
more likely to be females; however in clinical samples SAD seems to be 
more equally distributed among men and women.[4]
2. Diagnosis and clinical characteristics
SAD is characterised by an exaggerated and persistent fear of being 
negatively evaluated in social and performance situations.[6] The 
disorder is associated with physical, cognitive and behavioural 
disturbances. The generalised subtype consists of fears of most 
interactional and performance situations, while the non-generalised (or 
circumscribed) subtype is restricted to a few specific situations, such as 
public speaking or dating.[4,5] The generalised subtype or generalised 
social anxiety disorder (GSAD) is associated with greater comorbidity, 
chronicity, and functional impairment.[7] The avoidance of feared 
situations impacts on daily routine, work, academic and social activities 
and relationships. More than 80% of patients with SAD have a lifetime 
history of at least one other psychiatric disorder, most commonly major 
depression, panic disorder, generalised anxiety disorder, agoraphobia 
and substance use disorders.[5-7] There is also considerable overlap 
between SAD and avoidant personality disorder. [6,7]
SAD generally runs a chronic course and precedes mood, anxiety 
and substance use disorders. Even in the absence of comorbidity, SAD 
is associated with significant distress, including financial problems, 
increased suicidal thoughts, reduced work and school performance, 
poor social support and greater use of psychotropic medications.[5]
Despite significant suffering, only 50% of patients with SAD ever seek 
treatment and when they do, it is usually when a comorbid condition 
develops and necessitates treatment.[8]
3. Assessment
There are several aspects of the clinical presentation of patients with 
SAD that may impact on treatment decisions. 
First, it is important to assess the level of disability to help distinguish 
social phobia from shyness.[9] 
Second, SAD may be complicated by comorbid major depression, 
which is usually responsive to first-line therapy options (e.g. selective 
serotonin reuptake inhibitors (SSRIs) and dual-acting serotonin-
norepinephrine reuptake inhibitors (SNRIs)). Conversely, social anxiety 
symptoms should be excluded in patients presenting with depression, 
panic attacks restricted to social situations, or alcohol misuse. 
Third, in patients with alcohol and substance use disorders 
it is generally advisable to detoxify first, prior to commencing 
pharmacotherapy for SAD. 
Fourth, in women, pregnancy and lactation considerations may 
necessitate the use of a non-pharmacological intervention (e.g. 
cognitive-behavioural therapy) as first-line. 
Fifth, the presence of comorbid medical disorders and the 
prescription of concurrent medications must be borne in mind when 
using an anti-anxiety agent, particularly in view of the potential for 
drug-drug interactions and the potential impact of pharmacotherapy 
for SAD on underlying medical conditions. 
4. Treatment
4.1 Treatment goals
The need for treatment is determined by the severity and persistence 
of symptoms, the presence of comorbid psychiatric disorder or 
physical illness, the level of disability and impact on social functioning, 
concomitant medication, and a history of good response to, or poor 
tolerability of, previous treatment approaches. In line with this, the 
main goals of treatment in SAD are to treat core symptoms and 
comorbidities, reduce functional impairment and avoidance, and 
improve the quality of life.  
4.2 General aspects of treatment
Several treatment guidelines are available including those from 
the World Federation of Societies of Biological Psychiatry,[10] 
World Council on Anxiety,[11] the British Association for 
Psychopharmacology[9] and the Canadian Psychiatric Association.[12] 
Broadly speaking, these guidelines advocate for both pharmacological 
and non-pharmacological approaches in the management of SAD.
4.3 Acute treatment
Current evidence clearly supports the use of SSRIs (escitalopram, 
fluvoxamine, fluvoxamine controlled release (CR), paroxetine, 
sertraline) and the SNRI venlafaxine extended release (ER) as first-
line pharmacological agents in the treatment of GSAD. Improvement 
in symptoms should become manifest by week 4; however, up to 
12 weeks of treatment are needed to more definitively assess efficacy. 
In terms of psychotherapy, cognitive-behavioural therapy (CBT) 
is the treatment of choice. There is no conclusive evidence that 
pharmacotherapy is more effective than CBT or vice versa and the 
evidence in favour of the combination of pharmacotherapy and CBT 
is also limited.
4.4 Maintenance treatment
Drug treatment should be continued for a minimum period of 6 
months in patients who have responded at 12 weeks. Several long-
term studies (double-blind and open-label) have been conducted 
to examine the issue of relapse prevention.[13] These studies have 
evaluated moclobemide, phenelzine and CBT, sertraline and exposure 
therapy, fluvoxamine, paroxetine and escitalopram and venlafaxine 
ER. Response rates in these studies range from 58% for venlafaxine ER 
to 88% for escitalopram.
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4.5 Pharmacological treatment
Evidence from controlled trials indicates that SAD is responsive to a 
wide range of medication treatments.[4] Drugs recommended as first-
line treatment include SSRIs (escitalopram, fluvoxamine, paroxetine 
and sertraline) and the SNRI, venlafaxine. In a meta-analysis of 
efficacy of the SSRIs, which examined outcomes from 15 separate 
controlled studies (including trials of escitalopram, sertraline, 
paroxetine, fluoxetine and fluvoxamine), all agents with the exception 
of a single trial of fluoxetine (which did not separate from placebo), 
showed efficacy in ameliorating symptoms of SAD.[14] Venlafaxine has 
also been widely studied and venlafaxine ER has regulatory approval 
for SAD in a number of countries.[4] In a head-to-head comparison 
of venlafaxine and paroxetine, venlafaxine ER was as effective as 
paroxetine, and both drugs were better than placebo.[15] The efficacy 
of venlafaxine ER in SAD does not appear to be dose-related, i.e. lower 
(75 mg/day) and higher (150 - 225 mg/day) doses have produced 
similar therapeutic effects in trials.[16] The other SNRI, duloxetine, has 
not been studied in controlled trials for SAD. 
In addition to the SSRIs and venlafaxine, the monoamine 
oxidase inhibitor (MAOI) phenelzine and the reversible inhibitor of 
monoamine oxidase (RIMA) moclobemide have controlled evidence 
for efficacy. Phenelzine is not widely used because of its requirement 
of a low tyramine diet to prevent a hypertensive crisis. Moclobemide 
has demonstrated comparable effectiveness among patients with and 
without a comorbid anxiety disorder, as well as among patients with 
different SAD subtypes (generalised and non-generalised SAD).[17] 
There is preliminary evidence from randomised controlled trials 
for the efficacy of pregabalin and gabapentin. Open trials of other 
anticonvulsants (e.g. levetiracetam, tiagabine, topiramate) and the 
antipsychotic olanzapine show some promise as acute treatments, but 
adequate randomised controlled trials (RCTs) are lacking.[4,10]
Evidence for the efficacy of benzodiazepines (bromazepam and 
clonazepam) in SAD is mixed. 
Treatments with unproven efficacy in generalised social phobia 
include the tricyclic antidepressant imipramine, buspirone, and the 
beta-blocker, atenolol.[18]
4.6 Non-pharmacological treatment
The non-pharmacological treatment of choice for SAD is CBT or 
exposure therapy alone. CBT for social phobia includes techniques of 
psycho-education, in-session and in vivo exposure to feared situations, 
and techniques intended to modify maladaptive or irrational thinking 
patterns. Other techniques in the CBT umbrella are applied relaxation 
and social skills training. The relative efficacy of CBT vs exposure 
therapy is unclear, with some studies indicating comparable efficacy 
while other studies show somewhat greater efficacy for CBT.[4,10] In 
a recent meta-analysis of 32 RCTs that examined a variety of non-
pharmacological approaches, CBT was consistently shown to result 
in significantly greater improvements in SAD symptoms than other 
‘placebo’ conditions, such as supportive group therapy, self-exposure, 
being wait-listed (i.e. waiting for an intervention) or pill placebo.[19] 
4.7 Special populations
4.7.1 Pregnancy and lactation
The risks of drug treatment during pregnancy need to be weighed 
against the risks of withholding treatment for SAD. During the 
first trimester, SSRIs do not increase the risk of birth defects; the 
exception to this is paroxetine which is associated with a 1.5-fold 
increased risk of congenital heart defects.[20] Clinical guidelines 
recommend that paroxetine be discontinued during pregnancy. 
SSRIs taken after 20 weeks of gestation may be associated with an 
increased risk of persistent pulmonary hypertension in the neonate, 
and all antidepressants administered in the third trimester may 
cause discontinuation effects (e.g. increased muscle tone, irritability, 
disrupted sleep, jitteriness) although these tend to be mild and self-
limiting. There are no data, other than a single case report, on the safety 
of moclobemide during pregnancy, while there are limited data on the 
safety of the MAOIs. As animal studies are suggestive of teratogenicity 
and use of MAOIs necessitates dietary modifications, MAOIs are 
not considered first-line treatments for SAD in pregnancy. Newer 
antidepressants, such as venlafaxine, have been associated with poor 
neonatal adaptation syndrome (tremors, irritability, shivering, feeding 
disturbances, increased muscle tone, respiratory difficulties) although 
it is unclear whether this is the result of medication withdrawal 
or toxicity. Treatment is supportive and symptoms usually resolve 
within 2 weeks. In general, venlafaxine is considered to be moderately 
safe in pregnancy. Benzodiazepine use during pregnancy has been 
associated with neonatal morbidity, some congenital malformations 
such as orofacial cleft, and may be associated with an increased risk for 
preterm birth, low birth weight, floppy infant syndrome, and neonatal 
withdrawal symptoms. Clonazepam monotherapy, specifically, has 
not been associated with an increased risk of major malformations. 
Gabapentin has been shown to be teratogenic in mice; its safety in 
pregnant women has not been established and is best avoided during 
pregnancy.[20]
Long-term safety data on the use of antidepressants in pregnancy 
are lacking. Factors that are important to consider include the time 
between medication administration and feeding, and infant size and 
infant metabolism. Most SSRIs do not attain detectable levels in breast 
milk and are not associated with disturbed infant development or 
neuropathology. Sertraline and paroxetine may be good choices for 
lactating women as these SSRIs have specifically been associated with 
undetectable levels in infants. Benzodiazepines, such as clonazepam, 
diazepam and lorazepam, are excreted in breast milk. However, 
published data indicate that the levels detected in breast milk are low; 
thus the nursing infant is unlikely to ingest significant amounts of the 
drug in this way. Breastfeeding is possible, but the infant should be 
carefully monitored for any adverse effects.
4.7.2 Children and adolescents
Shyness in young children may be a precursor to SAD in adulthood. 
In children, common fears include fears about performance situations 
such as speaking or performing in front of people, social interactional 
fears such as joining in or starting a conversation, and interacting 
with same-age peers.[21] Unlike adults, children with SAD are seen as 
generally anxious and may experience more somatic symptoms, such 
as headaches, stomach aches and nausea, as a result of their anxiety. 
Impairments range from low self-esteem, social skills deficits, few 
friendships to scholastic underachievement. Among adolescents, typical 
fears include formal and informal social interactions, public observation 
and performance, and situations requiring assertive behaviour. In 
addition, adolescents seem to have more pervasive patterns of fear and 
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avoidance, as well as higher levels of social distress than either children 
or adults. SAD in childhood and adolescence is highly comorbid with 
depression. Comorbidity with anxiety and substance use disorders is 
also common.[21]
Compared with adults, there is relatively less information available 
on the safety, efficacy and long-term outcomes (relapse rates) of 
SSRI or SNRI treatment. Open-label and double-blind placebo-
controlled studies have shown response rates ranging from 36% to 
100%.[9-12] Fluoxetine, fluvoxamine, paroxetine and venlafaxine ER 
have been evaluated in RCTs. These agents have been well tolerated 
in children and adolescents in doses comparable to the adult dose. 
Antidepressants, in particular SSRI use, have come under the spotlight 
in recent years owing to concerns about their potential to increase 
suicidal ideation and attempts.[21] While the safety profile of SSRIs 
and other antidepressants specifically in children and adolescents 
with SAD is not yet known, a review of 24 short-term (4 - 16 weeks) 
trials involving nine antidepressant medications (including SSRIs) 
in more than 4 400 youth with major depressive disorder, obsessive-
compulsive disorder, and other psychiatric disorders, documented a 
4% rate of suicidal ideation and suicidal behaviours in patients treated 
with antidepressants compared with a 2% rate in patients treated with 
a placebo.[22] It is important to note that there were no completed 
suicides in any of these studies. 
CBT, as a 16-session treatment, has been shown to be an effective 
strategy in both children and adolescents with SAD, with continued 
improvement or maintenance of gains over a 1-year period.[21] The 
benefits of combining CBT and medication for childhood SAD have 
yet to be established.[21]
4.7.3 The elderly
The prevalence of SAD tends to decline in older adults (55 years of 
age and older). SAD is more common in elderly patients who have 
other psychiatric disorders, in particular major depression. Both 
pharmacological treatments (e.g. SSRIs, venlafaxine) and CBT are 
indicated for use in older adults with SAD; however, the standard of 
practice has been to infer from data in younger patients and assume 
their efficacy in older adults.[23] 
Several factors should be considered when selecting a medication for 
an older patient with SAD. Prior treatment response, target symptoms, 
concurrent physical illness and medications, and drug tolerability should 
all be taken into account. In order to reach the optimal dose for 
an older patient without causing intolerable side-effects, it is well 
worth remembering the adage ‘start low and go slow’.[23] Important 
considerations in pharmacological treatment in the elderly include 
heightened sensitivity for anticholinergic drug effects, increased 
sensitivity for extrapyramidal symptoms, an increased risk for orthostatic 
hypotension and electrocardiograph changes, and the possibility of 
paradoxical reactions (e.g. aggression) to benzodiazepines. SSRIs have 
been shown to be relatively safe and recommended doses of SSRIs for 
SAD are the same as for younger adults. However, the potential for 
SSRIs to cause gastrointestinal and other bleeds, hyponatraemia, postural 
hypotension and falls needs to be borne in mind in this age group.
4.8 Managing partial and non-responders
See steps 3 and 4 of algorithm below.
4.9 Algorithm
Step 1. Initiating treatment with pharmacotherapy/psychotherapy
Choose an evidence-based pharmacological or psychological therapy 
for the acute treatment of SAD.[9] Take account of patient clinical 
features, needs and preference when choosing treatment. If the 
decision is to start pharmacological treatment with an SSRI or SNRI, 
the starting dose can be low (sertraline 25 - 50 mg; paroxetine 10 - 
20 mg; venlafaxine 37.5 - 75 mg; fluvoxamine 25 - 50 mg; escitalopram 
5 - 10 mg), with titration up to a maximally tolerated therapeutic dose 
(Table 1). Although routine prescription of higher doses of SSRIs is 
not recommended,[9] individual patients may benefit from higher 
doses. For patients with comorbid mood (or anxiety) disorders, SSRIs 
may be preferred because of their broad spectrum of action. There is 
some evidence to suggest that major depressive disorder symptoms 
tend to resolve before an improvement in SAD symptoms is seen.[24] 
Evidence of symptom improvement should manifest by week 4. 
However, patients should be advised that treatment periods of up 
to 12 weeks are needed to assess efficacy, as there is some evidence 
from double-blind controlled trials to suggest that non-responders 
to treatment at 8 weeks become responders with 4 further weeks of 
double-blind treatment.[25]
Step 2. Maintaining a response and preventing relapse
Double-blind studies indicate that continuing SSRI or SNRI 
treatment from 12 weeks to 24 weeks (i.e. up to 6 months after 
initiation) is associated with an increase in overall treatment 
response rates. [9] Placebo-controlled relapse-prevention studies in 
patients who have responded to previous acute treatment also reveal 
Table 1. Recommended daily drug doses for social anxiety 
disorder[10]*
Selective serotonin reuptake inhibitors (SSRIs)
Escitalopram 10 - 20 mg
Paroxetine 20 - 50 mg
Sertraline 50 - 150 mg
Fluvoxamine 100 - 300 mg
Citalopram 20 - 40 mg
Fluoxetine 20 - 40 mg
Serotonin-norepinephrine reuptake inhibitors (SNRI)
Venlafaxine 75 - 225 mg
Monoamine oxidase inhibitor (MAOI)
Phenelzine 45 - 90 mg
Benzodiazepines
Clonazepam 1.5 - 8 mg
Anticonvulsant
Gabapentin 600 - 3 600 mg
Reversible inhibitor of monoamine oxidase (RIMA)
Moclobemide 300 - 600 mg
*Reprinted with permission from Bandelow B, Zohar J, Hollander E, et al. World Federation 
of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of 
anxiety, obsessive compulsive and post-traumatic stress disorders – first revision. World Journal of 
Biological Psychiatry 2008;9:248-312. Informa Healthcare. For educational purposes only.
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a significant advantage for staying on active medication (clonazepam, 
escitalopram, paroxetine, sertraline) for up to 6 months, compared 
with switching to placebo.[18] Therefore, continue drug treatment for 
at least another 6 months in patients who are responding at 12 weeks 
(i.e. show at least a 50% improvement in symptoms). Several of the 
guidelines recommend continuing treatment for at least 12 months. 
In patients at a high risk of relapse, it may be prudent to consider 
cognitive therapy after an adequate response to drug treatment. It 
is also vital that efficacy and tolerability are regularly monitored 
during long-term treatment.[9]
Step 3. Managing partial response
If after 12 weeks, there is only a 25 - 50% reduction in symptoms 
or a less than 25% reduction in symptoms, consider switching 
to venlafaxine after non-response to acute treatment with an 
SSRI. There is no clear evidence for the benefit of dose escalation 
after an initial non-response. Switching between treatments with 
proven efficacy is preferable. Alternative treatment strategies 
include a switch to non-SSRI antidepressants, anticonvulsants and 
benzodiazepines, as discussed above. 
Open-label augmentation of SSRI treatment with buspirone[26] has 
been reported as beneficial but placebo-controlled trials of pindolol 
augmentation and clonazepam augmentation, respectively, were not 
associated with greater treatment efficacy.[27,28] 
Step 4. Managing non-response
If there is still no response, re-evaluate the diagnosis and reassess for 
comorbid substance use disorders, undetected medical conditions, 
comorbid personality disorders, psychosocial stressors and poor 
compliance. Consider combining evidence-based pharmacological 
treatments only where there are no contraindications to doing so. An 
alternative strategy is to combine drug treatment with CBT. There 
is some preliminary evidence for the usefulness of this approach. [29] 
A recent randomised, double-blind placebo-controlled trial to 
determine whether combined medication and cognitive behavioural 
group treatment (CBGT) was superior to either monotherapy or 
pill placebo found that combined phenelzine and CBGT treatment 
was superior to either treatment alone and to placebo in terms 
of rates of response and remission.[30] D-cycloserine, a partial 
N-methyl-D-aspartate (NMDA) receptor agonist that facilitates fear 
extinction, has been documented in several trials to be useful as an 
augmentation to CBT in patients with SAD.  
5. Summary points
• SAD is highly responsive to evidence-based acute treatments:
• Pharmacological: most SSRIs (escitalopram, fluoxetine, fluvox-
amine, paroxetine, sertraline), venlafaxine, phenelzine, moclo-
bemide, some benzodiazepines (clonazepam), anticonvulsants 
(gabapentin, pregabalin) and olanzapine.
• Psychological: cognitive-behavioural therapy (CBT).
• There is no conclusive evidence that pharmacotherapy is more 
effective than CBT for the treatment of social phobia.
• Treatment duration of up to 12 weeks is needed to assess efficacy.
• Drug treatment should be continued for at least a further 6 months 
in patients who have responded at 12 weeks.
• Cost should be factored into the choice of medication; the most 
affordable medication should preferably be selected to allow for 
funding of the minimum period of suggested pharmacotherapy.
• In the longer term, consider CBT as this may reduce relapse rates 
better than drug treatment.
• Monitor efficacy and tolerability regularly during long-term 
treatment.
• Combining a drug and psychological approach is recommended 
during the initial phase of treatment.
• Consider switching to venlafaxine after non-response to acute 
treatment with an SSRI.
• Consider combining evidence-based pharmacological treatments if 
there is non-response but only where there are no contraindications 
to do so.
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